Table 1 Patients characteristics in the training, validation and test sets
Training | Validation | Test | |
|---|---|---|---|
Total | 117 | 39 | 39 |
Age (years) | |||
Mean | 53 | 52 | 56 |
Standard deviation | 14 | 15 | 17 |
FIGO stage | |||
FIGO I | 12 (10.2%) | 6 (15.4%) | 6 (15.4%) |
FIGO II | 70 (59.8%) | 22 (56.4%) | 22 (56.4%) |
FIGO III | 21 (18.0%) | 8 (20.5%) | 8 (20.5%) |
FIGO IV | 9 (7.7%) | 3 (7.7%) | 3 (7.7%) |
Unknown | 5 (4.3%) | 0 | 0 |
Volume at first BT fraction | |||
Less than 2.8 cc | 22 (18.8%) | 8 (12.8%) | 5 ( 20.5%) |
between 2.8 and 4.3 cc | 7 (6.0%) | 7 (17.9%) | 7 (17.9%) |
between 4.3 and 12.1 cc | 53 (42.3%) | 12 (30.8%) | 13 (33.3%) |
More than 12.1 cc | 35 (29.9%) | 12 (30.8%) | 14 (35.9%) |
Histopathological type | |||
Squamous cell carcinoma | 97 (82.9%) | 31 (79.5%) | 33 (84.6%) |
Adenocarcinoma | 16 (13.7%) | 6 (15.4%) | 4 (10.3%) |
Adeno-squamous cell carcinoma | 1(0. %) | 1 (2.6%) | 1 (2.6%) |
Non specified/unknown | 3 (2.5%) | 1 (2.5%) | 1 (2.5%) |
External beam radiotherapy scheme | |||
23 × 2 Gy | 95 (81.2%) | 29 (74.4%) | 32 (82.0%) |
25 × 1.8 Gy | 22 (18.8%) | 10 (25.6%) | 7 (18.0%) |